Cell Reports · 2023 · 11 citations · 37 references
Life SciencesMolecular BiologyOncologyCancer GeneticsGene ExpressionMolecular OncologyBladder CancerCancer Cell SignalingChromatinEpigenetic Regulation In CancerOncogenic Signaling PathwaysSignal Transduction In CancerCancer Signaling PathwaysCholesterol Biosynthesis ControlHuman TranscriptionMevalonate PathwayPharmacological Inhibition Of Cholesterol BiosynthesisTumor Growth DynamicsTumor Growth Rate
Dysregulation of transcription is a hallmark of cancer, including bladder cancer (BLCA). CRISPR-Cas9 screening using a lentivirus library with single guide RNAs (sgRNAs) targeting human transcription factors and chromatin modifiers is used to reveal genes critical for the proliferation and survival of BLCA cells. As a result, the nuclear transcription factor Y subunit gamma (NFYC)-37, but not NFYC-50, is observed to promote cell proliferation and tumor growth in BLCA. Mechanistically, NFYC-37 interacts with CBP and SREBP2 to activate mevalonate pathway transcription, promoting cholesterol biosynthesis. However, NFYC-50 recruits more of the arginine methyltransferase CARM1 than NFYC-37 to methylate CBP, which prevents the CBP-SREBP2 interaction and subsequently inhibits the mevalonate pathway. Importantly, statins targeting the mevalonate pathway can suppress NFYC-37-induced cell proliferation and tumor growth, indicating the need for conducting a clinical trial with statins for treating patients with BLCA and high NFYC-37 levels, as most patients with BLCA have high NFYC-37 levels.
37
BEDTools: a flexible suite of utilities for comparing genomic features
Aaron R. Quinlan, Ira M. Hall · Bioinformatics · 2010 · 30.4K citations · Full text
Model-based Analysis of ChIP-Seq (MACS)
Yong Zhang, Tao Liu, Clifford A. Meyer et al. · Genome biology · 2008 · 19.9K citations · Full text